FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1597431566> ?p ?o ?g. }

• W1597431566 endingPage "236" @default.
• W1597431566 startingPage "229" @default.
• W1597431566 abstract "This study assessed whether treatment with a beta-adrenergic blocking agent in addition to the use of the angiotensin-converting enzyme (ACE) inhibitor captopril decreases cardiovascular mortality and morbidity in patients with asymptomatic left ventricular dysfunction after myocardial infarction (MI) and whether the presence of neurohumoral activation at the time of hospital discharge predicts the effects of beta-blocker treatment in these patients.Both beta-blockers and ACE inhibitors have been shown to have beneficial effects in patients with left ventricular dysfunction but no overt heart failure after MI. These patients often have persistent neurohumoral activation at the time of hospital discharge, and one would expect that patients with activation of the sympathetic nervous system derive the most benefit from treatment with beta-blockers. However, beta-blockers are underutilized in this high risk group of patients, and it is unknown whether their beneficial effects are additive to those of ACE inhibitors.We performed a retrospective analysis of data from the Survival and Ventricular Enlargement (SAVE) study and its neurohumoral substudy. The relations between beta-blocker use at the time of randomization and neurohumoral activation and the subsequent development of cardiovascular events were analyzed by use of Cox proportional hazards models controlling for covariates.After adjustment for baseline imbalances, beta-blocker use was associated with a significant reduction in risk of cardiovascular death (30%, 95% confidence interval [CI] 12% to 44%) and development of heart failure (21%, 95% CI 3% to 36%), but the reduction in recurrent MI (11%, 95% CI 13% to 31%) was not significant. These reductions were independent of the use of captopril. Beta-blockers were not found to have a greater effect in patients with neurohumoral activation at the time of hospital discharge.The beneficial effects of beta-blocker use at the time of hospital discharge in patients with asymptomatic left ventricular dysfunction after MI appear to be additive to those of captopril and other interventions known to improve prognosis. Neurohumoral activation at the time of hospital discharge fails to identify those patients who will derive the greatest benefit from treatment with beta-blockers." @default.
• W1597431566 created "2016-06-24" @default.
• W1597431566 creator A5009342484 @default.
• W1597431566 creator A5026106434 @default.
• W1597431566 creator A5031409917 @default.
• W1597431566 creator A5031560506 @default.
• W1597431566 creator A5033665054 @default.
• W1597431566 creator A5045775390 @default.
• W1597431566 creator A5054349218 @default.
• W1597431566 creator A5059584372 @default.
• W1597431566 creator A5080836636 @default.
• W1597431566 date "1997-02-01" @default.
• W1597431566 modified "2023-10-16" @default.
• W1597431566 title "Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada." @default.
• W1597431566 cites W1966953116 @default.
• W1597431566 cites W1967382962 @default.
• W1597431566 cites W1967720231 @default.
• W1597431566 cites W1968355808 @default.
• W1597431566 cites W1975363479 @default.
• W1597431566 cites W1984872916 @default.
• W1597431566 cites W1995546178 @default.
• W1597431566 cites W1997062534 @default.
• W1597431566 cites W2004114486 @default.
• W1597431566 cites W2020883986 @default.
• W1597431566 cites W2036123834 @default.
• W1597431566 cites W2036770224 @default.
• W1597431566 cites W2044066871 @default.
• W1597431566 cites W2048741316 @default.
• W1597431566 cites W2048771024 @default.
• W1597431566 cites W2077477680 @default.
• W1597431566 cites W2080700387 @default.
• W1597431566 cites W2095000996 @default.
• W1597431566 cites W2260631166 @default.
• W1597431566 cites W2312388685 @default.
• W1597431566 cites W2338638760 @default.
• W1597431566 cites W2904299326 @default.
• W1597431566 cites W4241692877 @default.
• W1597431566 doi "https://doi.org/10.1016/s0735-1097(96)00489-5" @default.
• W1597431566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9014971" @default.
• W1597431566 hasPublicationYear "1997" @default.
• W1597431566 type Work @default.
• W1597431566 sameAs 1597431566 @default.
• W1597431566 citedByCount "242" @default.
• W1597431566 countsByYear W15974315662012 @default.
• W1597431566 countsByYear W15974315662013 @default.
• W1597431566 countsByYear W15974315662014 @default.
• W1597431566 countsByYear W15974315662015 @default.
• W1597431566 countsByYear W15974315662016 @default.
• W1597431566 countsByYear W15974315662017 @default.
• W1597431566 countsByYear W15974315662018 @default.
• W1597431566 countsByYear W15974315662019 @default.
• W1597431566 countsByYear W15974315662020 @default.
• W1597431566 countsByYear W15974315662021 @default.
• W1597431566 countsByYear W15974315662022 @default.
• W1597431566 countsByYear W15974315662023 @default.
• W1597431566 crossrefType "journal-article" @default.
• W1597431566 hasAuthorship W1597431566A5009342484 @default.
• W1597431566 hasAuthorship W1597431566A5026106434 @default.
• W1597431566 hasAuthorship W1597431566A5031409917 @default.
• W1597431566 hasAuthorship W1597431566A5031560506 @default.
• W1597431566 hasAuthorship W1597431566A5033665054 @default.
• W1597431566 hasAuthorship W1597431566A5045775390 @default.
• W1597431566 hasAuthorship W1597431566A5054349218 @default.
• W1597431566 hasAuthorship W1597431566A5059584372 @default.
• W1597431566 hasAuthorship W1597431566A5080836636 @default.
• W1597431566 hasBestOaLocation W15974315661 @default.
• W1597431566 hasConcept C126322002 @default.
• W1597431566 hasConcept C164705383 @default.
• W1597431566 hasConcept C207103383 @default.
• W1597431566 hasConcept C27016395 @default.
• W1597431566 hasConcept C2778198053 @default.
• W1597431566 hasConcept C2778742482 @default.
• W1597431566 hasConcept C2779479957 @default.
• W1597431566 hasConcept C2779611605 @default.
• W1597431566 hasConcept C44249647 @default.
• W1597431566 hasConcept C500558357 @default.
• W1597431566 hasConcept C50382708 @default.
• W1597431566 hasConcept C71924100 @default.
• W1597431566 hasConcept C84393581 @default.
• W1597431566 hasConceptScore W1597431566C126322002 @default.
• W1597431566 hasConceptScore W1597431566C164705383 @default.
• W1597431566 hasConceptScore W1597431566C207103383 @default.
• W1597431566 hasConceptScore W1597431566C27016395 @default.
• W1597431566 hasConceptScore W1597431566C2778198053 @default.
• W1597431566 hasConceptScore W1597431566C2778742482 @default.
• W1597431566 hasConceptScore W1597431566C2779479957 @default.
• W1597431566 hasConceptScore W1597431566C2779611605 @default.
• W1597431566 hasConceptScore W1597431566C44249647 @default.
• W1597431566 hasConceptScore W1597431566C500558357 @default.
• W1597431566 hasConceptScore W1597431566C50382708 @default.
• W1597431566 hasConceptScore W1597431566C71924100 @default.
• W1597431566 hasConceptScore W1597431566C84393581 @default.
• W1597431566 hasIssue "2" @default.
• W1597431566 hasLocation W15974315661 @default.
• W1597431566 hasLocation W15974315662 @default.
• W1597431566 hasOpenAccess W1597431566 @default.
• W1597431566 hasPrimaryLocation W15974315661 @default.
• W1597431566 hasRelatedWork W1969470184 @default.

• next